<DOC>
	<DOCNO>NCT00018174</DOCNO>
	<brief_summary>This project treatment-matching study test whether add antidepressant pharmacotherapy behavioral cessation treatment improve depression-prone smoker 's ability quit , undermine cessation goal smoker lack history depression . The study target randomize 120 smoker prior history depression 120 smoker lack history double-blind treatment either 60 mg fluoxetine placebo , undergo cognitive behavioral treatment quit smoking .</brief_summary>
	<brief_title>Fluoxetine Quit Smoking Aid Depression-Prone Smokers</brief_title>
	<detailed_description>The aim research examine whether add antidepressant pharmacotherapy behavioral cessation treatment improve depression-prone smoker 's ability quit , undermine cessation smoker lack history depression , randomize smoker without history double-blind treatment either 60 mg fluoxetine placebo . The primary Depressive Episode Hypothesis state stress quit smoke biological challenge nicotine withdrawal trigger depressive episode vulnerable individual . To extent episode onset prevent prophylactic administration antidepressant pharmacotherapy , smoker history depression show significantly high abstinence rate treat fluoxetine placebo , whereas drug effect evident history negative smoker lack depressive diathesis . An alternative generalized withdrawal hypothesis construe post-cessation dysphoria one general manifestation nicotine withdrawal syndrome occur independently depressive vulnerability , predict fluoxetine , compare placebo , uniformly improve cessation outcome , regardless whether smoker possess diathesis depression . Over period four year , study hope randomize 120 smoker history depression 120 smoker lack history double-blind treatment either 60 mg fluoxetine placebo , undergo group cognitive behavioral treatment quit smoking . To allow plasma drug level stabilize quit smoking , drug placebo treatment begin 3 week quit smoking continue additional 8 week follow quit date . Participants follow monthly 4 month end treatment order ass main study outcome ; abstinence smoke 6 month quit date .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Subjects 144 smoker experience least one episode major depressive disorder 206 smoker lack lifetime history major depressive disorder . None currently meet diagnostic criterion major depression , meet criterion past 6 month . All male female community member age 18 65 smoker least 10 cigarette day past year . Subjects may enter trial : 1. take monoamine oxidase inhibitor , antidepressant , antianxiety agent , lithium , tryptophan phenothiazine within past month ; 2. treat hypertension guanethidine , reserpine , thiazide diuretic , beta blocker , clonidine ; 3. take Type IC antiarrhythmic ( e.g. , propafenone flecanide ) highly proteinbound drug ( e.g. , warfarin , digitoxin ) ; 4. medically unstable condition major health event past 6 month ( e.g. , myocardial infarct major surgery ) ; 5. CBC value 10 % outside normal limit , liver enzymes exceed 40 % upper limit normal ; 6. history severe allergy , multiple adverse drug reaction know allergy fluoxetine ; 7. actively abuse alcohol drug receive inpatient treatment substance abuse within past year ; 8. use nicotine replacement ; 9. pregnant , lactating , childbearing potential ; 10. present current evidence organic brain disease , definite subclinical major depressive disorder serious suicidal risk posttraumatic stress disorder , premenstrual dysphoric disorder ; 11. score great 14 21item Hamilton Depression Rating Scale great 15 Beck Depression Inventory ; 12. history seizure , mania hypomania , psychosis . Individuals bipolar disorder , PTSD , schizophrenia exclude might respond adversely fluoxetine . Subjects dysthymic disorder anxiety disorder study current symptom sequelae episode major depression . Excluding case would purify sample remove mild degree dysphoria , would greatly restrict ability generalize treatment implication current population smoker .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Depression</keyword>
	<keyword>Fluoxetine</keyword>
	<keyword>Nicotine dependence</keyword>
</DOC>